Navigation Links
Amylin Pharmaceuticals Reports First Quarter Financial Results
Date:4/21/2008

discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 1,900 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA or SYMLIN may be affected by competition, unexpected new data, technical issues, or manufacturing and supply issues; risks that our financial results may fluctuate significantly from period to period and may not meet market expectations; risks that any financial guidance we provide may not be accurate; risks that our clinical trials will not be completed when planned or may not replicate previous results; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates, or sNDAs for label expansion requests, such as the BYETTA monotherapy sNDA, may not be submitted timely or receive FDA approval; risks that we may not be able to complete our manufacturing facility on a timely basis; and other risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA or SYMLIN. These and additional risks and uncertainties are described more fully in the Company's recently filed Form 10-Q. Amylin disclaims any obligation to update these forward-loo
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Present at Research & Development Day
5. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
6. Amylin Pharmaceuticals Reports 2007 Financial Results
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... February 26, 2015 March is sure ... of Traditional Chinese Medicine (ACTCM). ACTCM is announcing their ... the Chinese New Year celebration and including several webinars, ... as follows: , Sunday, March 1 – ACTCM Chinese ... celebrates the Chinese New Year with lion dancers, free ...
(Date:2/26/2015)... February 26, 2015 As the great ... looking for deeper meaning, more substantial roles and connections ... how do I live a life that still matters? ... of Younger Next Year Total Immersion Retreat , ... program boasts unbelievable results and jump-starts a healthier life. ...
(Date:2/26/2015)... February 26, 2015 “In the last ... monitored the evolution of one of the newest hair ... ARTAS system offers a machinery that facilitates the ... the patient’s scalp,” said Dr. Parsa Mohebi. , Although ... the speed at which the device extracted these grafts ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Dr. Parsa Mohebi, ... his hair transplant contest winner’s surgery on Friday, ... winner Marc R., is all set to receive his grand ... ARTAS system. His procedure will be done on a live ... To watch the surgery, go to the website and experience ...
(Date:2/26/2015)... 26, 2015 Thousands of people in ... fund powerful progress for the Muscular Dystrophy Association during ... funds and awareness that will help save and improve ... , “MDA Muscle Walk events unite and rally communities ... abilities to move are compromised — including everyday abilities ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces March Schedule of Events 2Health News:The Aspen Club on Actively Aging: Telling a New Story on Aging 2Health News:Newest Technology now Available at Parsa Mohebi Hair Restoration 2Health News:Hair Transplant Contest Winner’s Surgery to be Streamed LIVE 2Health News:MDA Kicks-Off Annual Muscle Walk Season in Local Communities Nationwide to Fight Back Against Muscle Disease 2Health News:MDA Kicks-Off Annual Muscle Walk Season in Local Communities Nationwide to Fight Back Against Muscle Disease 3
... ... , ... 16, 2010 -- PureSafety , a leading provider of results-driven software and information solutions ... health and safety (EHS) professionals, today announced the launch of Future Leaders in EHS ...
... , INNISBROOK, Fla., Feb. 16 ... representing the world,s finest and details of an enhanced week-long tournament ... the connection between healthy sight and optimum sports performance. , Most ... Stricker , Jim Furyk and Kenny Perry ...
... Health and the University of Colorado School of Medicine have ... remarkably effective in mice. In the February 16 issue of ... ( PNAS ), Kimberly Jordan, PhD, Jill Slansky, PhD, and ... vaccinated with a peptide they developed remained alive and tumor-free ...
... drugs often hit other non-cancerous cells, causing patients to get ... just the cancer cells? Researchers at the Georgia Institute of ... just that. In the online journal BMC Cancer ... 100 nanometers in size - to sneak a particular type ...
... study has revealed that certain breast cancer genetic variants ... density and breast cancer. Professor John Hopper of ... greatly in their underlying risk of breast cancer. "These ... the development of breast cancer." "We hope our ...
... Bethesda, MD (Feb. 16, 2010) Certain patients ... and Crohn,s disease of the colon, have an ... individuals without IBD. A number of factors contribute ... individualized and sensible approach to surveillance in patients, ...
Cached Medicine News:Health News:PureSafety and EHS Today Launch Future Leaders in EHS 2Health News:PureSafety and EHS Today Launch Future Leaders in EHS 3Health News:Transitions Championship Announces Strongest Field to Date and a Vision Like No Other on the PGA TOUR(R) 2Health News:Transitions Championship Announces Strongest Field to Date and a Vision Like No Other on the PGA TOUR(R) 3Health News:Transitions Championship Announces Strongest Field to Date and a Vision Like No Other on the PGA TOUR(R) 4Health News:Transitions Championship Announces Strongest Field to Date and a Vision Like No Other on the PGA TOUR(R) 5Health News:New strategy produces promising advance in cancer vaccines 2Health News:Attacking cancer cells with hydrogel nanoparticles 2Health News:Study reveals genetic link between mammographic density and breast cancer 2Health News:AGA offers new recommendations for CRC surveillance for certain patients with IBD 2Health News:AGA offers new recommendations for CRC surveillance for certain patients with IBD 3
(Date:2/26/2015)... , Feb. 26, 2015 Integrity Applications, ... the GlucoTrack ® model DF-F, a noninvasive  device that ... Lutz Heinemann , Ph.D., will head its new scientific ... leaders in the field of Diabetes research, monitoring and ... Ph.D has been Chief Executive Officer and Head, Business ...
(Date:2/26/2015)... February 26, 2015 Vectorious ... cardiac monitoring system for patients suffering from congestive ... closed a $5 million financing round. Investors in ... owned jointly by Yehuda Zisapel and Prof. ... Gilon, Gur Muntzer and others; and the U.S.-based ...
(Date:2/26/2015)... 2015 Columbia Laboratories, Inc. (Nasdaq: ... specialty pharmaceutical company focused on the development of ... Phase II clinical trial for COL-1077, a lidocaine ... endometrial biopsy in the second quarter of 2015. ... feedback from the United States Food and Drug ...
Breaking Medicine Technology:Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 3Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 4Vectorious Medical Technologies Completes $5M Raise 2Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015 2Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015 3
... Society of NeuroInterventional Surgery ... Annual ... from,the US and Argentina reveal that a new minimally invasive procedure,successfully ... that, in severe form, can cripple sufferers.,Announced today at the Society ...
... 29 Echo Therapeutics,(OTC Bulletin Board: ECTE) ... of its Symphony(TM) Transdermal Continuous Glucose Monitoring ... Type 2 Diabetes. Echo,s non-invasive,Symphony tCGM System ... technologies and the Prelude(TM) SkinPrep System, which,incorporates ...
Cached Medicine Technology:New Minimally Invasive Surgical Procedure Restores Quality of Life in Patients With Potentially Debilitating Spinal Condition 2New Minimally Invasive Surgical Procedure Restores Quality of Life in Patients With Potentially Debilitating Spinal Condition 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 4
... qualitative assay for rapid detection of Strep A ... A test excels at detection of Strep A ... samples. This CLIA Waived test uses a convenient ... A leaves little chance for misdiagnosis, minimizing the ...
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
...
... is designed to meet the most demanding ... being one of the safest, most comfortable, ... routine wax sections and specialized resin work, ... quality sections without the the inconvenience of ...
Medicine Products: